ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.
The AI program also correctly identified 90% of true positive cases, according to new data presented at the Society for Breast Imaging's annual symposium.